The anti-CD25 Antibody Daclizumab Inhibits Inflammation and Stabilizes Disease Progression in MS

OBJECTIVE: To answer three important questions related to the efficacy of daclizumab in multiple sclerosis (MS): 1. Is the therapeutic effect of daclizumab dependent on combination with IFN-β? 2. Is a higher dose of daclizumab more efficacious in patients with persistent disease activity? 3. Can bio...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bielekova, Bibiana, Howard, Thomas, Packer, Amy N., Richert, Nancy, Blevins, Gregg, Ohayon, Joan, Waldmann, Thomas A., McFarland, Henry F., Martin, Roland
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2742781/
https://ncbi.nlm.nih.gov/pubmed/19364933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2009.50
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak